Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 81-84 , 15 May 2010

The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia

  • Taiji Tsunemi

      Affiliations

    • Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    • Department of Pediatrics, University of California, San Diego, La Jolla, CA, United States
    • Corresponding Author InformationCorresponding author. Department of Pediatrics, University of California, San Diego, 9500 Gilman Dr. MC 0642, La Jolla CA 92093, United States. Tel.: +1 858 246 0187; fax: +1 858 246 0162.
    • ,
  • Kinya Ishikawa

      Affiliations

    • Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    • ,
  • Kei Tsukui

      Affiliations

    • Department of Otolaryngology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    • ,
  • Takuro Sumi

      Affiliations

    • Department of Otolaryngology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    • ,
  • Ken Kitamura

      Affiliations

    • Department of Otolaryngology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    • ,
  • Hidehiro Mizusawa

      Affiliations

    • Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan

Received 16 August 2009 ,Revised 22 January 2010 ,Accepted 26 January 2010.

References 

  1. Hille B. Ionic channels of excitable membranes. 3rd Edn.. Sunderland, MA: Sinauer Associates; 2001;
  2. Mainero C, Inghilleri M, Pantano P, Conte A, Lenzi D, Frasca V, et al. Enhanced brain motor activity in patients with MS after a single dose of 3, 4-diaminopyridine. Neurology. 2004;62:2044–2050
  3. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert–Eaton myasthenic syndrome. Neurology. 2000;54:603
  4. Strupp M, Schüler O, Krafczyk S, Jahn K, Schautzer F, Büttner U, et al. Treatment of downbeat nystagmus with 3, 4-diaminopyridine: a placebo-controlled study. Neurology. 2003;61:165–170
  5. Sprenger A, Zils E, Rambold H, Sander T, Helmchen C. Effect of 3, 4-diaminopyridine on the postural control in patients with downbeat nystagmus. Ann N Y Acad Sci. 2005;1039:395–403
  6. Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci. 1997;145:205–211
  7. Yabe I, Kitagawa M, Suzuki Y, Fujiwara K, Wada T, Tsubuku T, et al. Positional vertigo and macroscopic downbeat positioning nystagmus in spinocerebellar ataxia type 6 (SCA6). J Neurol. 2003;250:440–443
  8. Ishikawa K, Mizusawa H. On autosomal dominant cerebellar ataxia (ADCA) other than polyglutamine diseases, with special reference to chromosome 16q22.1-linked ADCA. Neuropathology. 2006;26:352–360
  9. Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology. 1992;42:1938–1943
  10. Kordasiewicz HB, Gomez CM. Molecular pathogenesis of spinocerebellar ataxia type 6. Neurotherapeutics. 2007;4:285–294
  11. Leigh RJ. Potassium channels, the cerebellum, and treatment for downbeat nystagmus. Neurology. 2003;61:158–159
  12. Bradley WG, Daroff RB, Fenichel G, Jankovic J. Neurology in clinical practice edition. 5rd Edn.. Stoneham: Butterworth-Heinemann; 2008;

PII: S0022-510X(10)00051-1

doi: 10.1016/j.jns.2010.01.021

Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 81-84 , 15 May 2010

Article Tools

* Image Usage & Resolution